Navigation Links
Wolters Kluwer Health Appoints Anne Woods to Chief Nursing Officer; Strengthens Its Commitment to the Nursing Market
Date:11/5/2009

NEW YORK, Nov. 5 /PRNewswire/ -- Wolters Kluwer Health has announced the appointment of Anne Dabrow Woods, MSN, RN, CRNP, ANP-BC, to the new position of Chief Nursing Officer (CNO) in a move to strengthen the nursing strategy of its Lippincott Williams & Wilkins (LWW) journals and Ovid brands. LWW is a leading international publisher of medical and nursing journals; Ovid is the global leader in electronic medical, scientific, and academic information research solutions.

"I am delighted to have Anne in this new role as Chief Nursing Officer to help lead our nursing strategy and commitment to this important customer base for both LWW and Ovid," said Karen Abramson, President and CEO of Wolters Kluwer Health Medical Research. "Anne's nursing practice experience, combined with her editorial and publishing career, provides a unique perspective on the issues and information access needs of nursing professionals throughout their careers -- from education and research to clinical practice."

As CNO, Woods will lead the nursing strategy across both the LWW journals and Ovid businesses. She will provide important direction on the development of nursing products based on her knowledge of how nurses access and use information in their practice to improve patient outcomes. In addition, Woods will have a visible role within the nursing profession's medical and nursing societies and industry associations, many of which utilize Wolters Kluwer Health to support their electronic content strategies.

Woods has been with Wolters Kluwer Health for 11 years in a variety of positions, including Clinical Editor, Clinical Director, Publisher, and most recently the Director of Journal Strategy & Development. She will continue her position as publisher, American Journal of Nursing (AJN), along with her new responsibilities as CNO. Woods has been a nurse for over 25 years and a nurse practitioner for over 11 years, with extensive experi
'/>"/>

SOURCE Wolters Kluwer Health
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Wolters Kluwer Health Introduces Formulary Facts(TM), a Formulary Analytics Tool that Sets the Standard for Accuracy and Ease-of-Use
2. Wolters Kluwer Health Appoints Susan Driscoll as Executive Vice President & General Manager of the Books Business of its Professional & Education Unit
3. Wolters Kluwer Health Appoints Scott Lubeck Vice President, Technology of its Professional & Education Unit
4. Wolters Kluwer Appoints Robert Becker as President and CEO Wolters Kluwer Health; and Stacey Caywood as President and CEO Wolters Kluwer Law & Business (U.S.)
5. Wolters Kluwer Healths Unique Prescription Data Tapped by FDA in Effort to Advance Drug Safety
6. Cogdell Spencer Names Herritz and Wolters to Key Leadership Positions Within Erdman
7. Wolters Kluwer Health Customer Service Organization Awarded Center of Excellence Certification
8. Wolters Kluwer Healths New Forecasting Service Models Pharmas Future
9. Wolters Kluwer Health Launches Interactive Platform for Pharmacology Journal Content
10. Penn study finds pro-death proteins required to regulate healthy immune function
11. UCLA researchers identify markers that may predict diabetes in still-healthy people

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...atory consulting firm Emergo Group recently survey...ors and industry service providers about the state...nd their outlook for 2010. , ...bal medical device regulatory consulting firm Em...nd IVD manufacturers, distributors and industry se...
(Date:11/24/2009)... be coupled with Stem Cell Therapy. , ...09 -- Entest Biomedical, Inc. (OTCBB: ENTB) anno...ufacturer of lasers regarding the development of a...Entest and used in conjunction with several stem c... These therapies are aimed at increasing efficacy ...
(Date:11/24/2009)...will be offering a free online seminar (webinar) o...d certified ophthalmologist and pioneer in LASIK s... , (Vocus) November 23, 20...nar on LASIK Vision Correction – which can b...is free to anyone attending., , ,The webinar is pr...
(Date:11/24/2009)...-USFarms,Inc.,(PinkSheets:USFM)adiversifiedsupplie...nounceithasreceivedformalcertificationapprovalbyth...M)Juiceproduct. ,, YanSkwara,CEOofUSFarms,Inc.s...edthecertificationprocesswiththeAmericanVegetarian...goaloftheAVAistoprovideawidelyrecognizedcertificat...
(Date:11/24/2009)...CountyHeathcare(LCH)isasmallhealthsystemontherugge...munities,employingmorethan1,200fullandpart-timepeo...uccessfulbackup,you,renotdoingyourjob,"saysBrooksB...hecasewithmanyhospitalsinMaine,budgetsareextremely...rotecthismissioncriticalsystems.Hedrewupaplan,went...
Breaking Medicine News(10 mins):Health News:Medical Device Industry Positive About 2010 – Survey 2Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Free LASIK Surgery Webinar 2Health News:Free LASIK Surgery Webinar 3Health News:Free LASIK Surgery Webinar 4Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
... Delhi Cabinet today cleared the business model fo...ary Sciences (ILBS) being set up in the capital. /...eeting chaired by Chief Minister Sheila Dikshit wo...edical equipment would be borne by Delhi Governmen...
... Zolpidem is usually used to treat insomnia. T...ied for a period of six months by South African re...eveal that they are in a condition where keeping e... Zolpidem was given to the patients every morn...
... There appears to be a ray of hope for men, who ar...on with no remedy from available treatment measure...where the animal’s very own penile cells were used...s were introduced with a graft made from manufactu...
... Scott and Nicola Smith of Leicester parents of si...ffering from the incurable disorder Adrenoleukodys...ading to hear came true yesterday with reports ind...e nearly always male who lose sight, hearing, and ...
... The results of a new study shows that people with...to develop heart failure in middle age, the result...ome means a cluster of conditions, including obesi...disease, stroke and diabetes. A team of Swedish re...
... Researchers from the University of Florida announ...hickens with a disease that otherwise would have l...e researchers hope that the gene therapy may one d... the research, which delayed the onset of blindnes...
Other Medicine News:Health News:A Mother Passes On A Rare, Terminal Brain Disease To Her Three Children 2Health News:Gene Therapy May Help Restore Sight In Congenital blindness 2
(Date:11/24/2009)...v.24/PRNewswire/--AFOXThanksgivingDaytelevisionspe....S.remindsviewersthattheholidaysareatimetobegratef...rallthosewhofightthatbattleeachdayassurvivors,care...hehistoricreturntotheiceofcancersurvivorsScottHami...on-JohnandDavidFosterwhowillperform"HopeisAlwaysHe...
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,...oparticipatinginaschemetodefraudtheExport-ImportBa...announcedAssistantAttorneyGeneraloftheCriminalDivi....GratacosoftheEx-ImBank,OfficeoftheInspectorGenera...obertsinU.S.DistrictCourtinWashingtontoaone-countc...
(Date:11/23/2009)...a.,Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasd...ment-reagentsystemstothebloodtransfusionindustry,t...Jaffray21stAnnualHealthCareConferenceinNewYork,NYw...TheCompany,spresentationisscheduledforTuesday,Dece...ntationwillbeavailablethroughthe"AboutUs--Investor...
Breaking Medicine Technology:FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 1Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 3Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 1Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
...SAN MATEO, Calif., Oct. 3 Anthera Pharmaceuticals...developing,anti-inflammatory therapeutics for chro...y the completion of enrollment and patient dosing ...d, A-002 for stable coronary,artery disease. Data ...f,the year. "We are pleased with the rapid enroll...
...NEW YORK, Oct. 2 ImClone Systems Incorporated,(Na...SE: BMY ) today announced,that the U.S. Food and ...o,the ERBITUX(R) (Cetuximab) product labeling to i...epidermal growth factor inhibitor,(EGFR)-expressin...er,failure of both irinotecan- and oxaliplatin-bas...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
TPS-TL Spinal Spacer
...esorbable, osteoconductive matrix consisting of hy...ared for use in oral maxillofacial procedures as a...g Pro Osteon 200R has been FDA indicated as a bone...h bone during the healing process. Its interconnec...
O-arm Complete Multidimensional Surgical Imaging
Merlin Patient Care System
Medicine Products: